Vivani Medical
Vivani Medical
VANI
NASDAQ
1.04
USD
0.00%
About
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively.
Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division.
The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 61.0K |
| Three Month Average Volume | 7.3M |
| High Low | |
| Fifty-Two Week High | 7.8 USD |
| Fifty-Two Week Low | 0.84 USD |
| Fifty-Two Week High Date | 28 Feb 2024 |
| Fifty-Two Week Low Date | 21 Dec 2023 |
| Price and Volume | |
| Current Price | 1.31 USD |
| Beta | 3 |
| Relative Price Change | |
| Four Week Relative Price Change | 3.33% |
| Thirteen Week Relative Price Change | -24.91% |
| Twenty-Six Week Relative Price Change | -61.44% |
| Fifty-Two Week Relative Price Change | 13.01% |
| Year-to-Date Relative Price Change | 8.45% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -19.63% |
| Twenty-Six Week Price Change | -57.61% |
| Five Day Price Change | -3.68% |
| Fifty-Two Week Price Change | 41.61% |
| Year-to-Date Price Change | 28.43% |
| Month-to-Date Price Change | 6.50% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.40683 USD |
| Book Value Per Share (Most Recent Quarter) | 0.43162 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.40683 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.43162 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.47612 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.50443 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.46427 USD |
| Normalized (Last Fiscal Year) | -0.50443 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.50443 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.46427 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.50443 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.46427 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.40473 USD |
| Cash Per Share (Most Recent Quarter) | 0.45146 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.49657 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.45573 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.41149 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2,906 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -2,868.72% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -2,933.18% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -2,868.72% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -15.95% |
| Tangible Book Value (5 Year) | 46.43% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 40.33% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 24.24% |
| EPS Change (Trailing Twelve Months) | -16.40% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -24,919,000 |
| Net Debt (Last Fiscal Year) | -20,654,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -24,586,000 |
| Free Cash Flow (Trailing Twelve Months) | -21,521,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -52.93% |
| Return on Assets (Trailing Twelve Months) | -44.89% |
| Return on Assets (5 Year) | -56.58% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -78.85% |
| Return on Equity (Trailing Twelve Months) | -86.10% |
| Return on Equity (5 Year) | -73.88% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -60.80% |
| Return on Investment (Trailing Twelve Months) | -50.97% |
| Return on Investment (5 Year) | -67.66% |